Literature DB >> 8049650

Radiotherapy in early stage Hodgkin's disease.

P L Zinzani1, E Barbieri, F Gherlinzoni, G Frezza, P Mazza, A Pica, I Ammendolia, M Bendandi, S Neri, G Miniaci.   

Abstract

Ninety-nine patients with "standard risk" Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one patients (21%) relapsed, 17 of whom (81%) obtained a second complete remission. The projected 9-year overall survival and disease-free survival were 95% and 78%, respectively. In this study our goals were to reduce the irradiation volumes, to decrease the number of splenectomies performed at diagnosis, and to utilize radiotherapy alone in these patients. We were able to reduce the irradiation volumes in over 50% and 80% of the patients with disease in the upper torso and subdiaphragm, respectively. Furthermore, this therapeutic approach permitted us to reduce the acute and long-term toxic effects related to splenectomy and combined modality treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049650     DOI: 10.3109/10428199409056292

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.

Authors:  Tianling Wei; Edyta Biskup; Lise Mette Rahbek Gjerdrum; Omid Niazi; Niels Ødum; Robert Gniadecki
Journal:  Oncotarget       Date:  2016-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.